lutetium has been researched along with Invasiveness, Neoplasm in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brandt-Larsen, M; Juhl, K; Kjaer, A; Madsen, J; Persson, M; Ploug, M; Rasmussen, P | 1 |
| Kjaer, A; Madsen, J; Persson, M; Ploug, M; Rasmussen, P | 1 |
2 other study(ies) available for lutetium and Invasiveness, Neoplasm
| Article | Year |
|---|---|
uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
Topics: Animals; Cell Line, Tumor; Coordination Complexes; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Inhibitory Concentration 50; Ligands; Lutetium; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Protein Binding; Radioisotopes; Receptors, Urokinase Plasminogen Activator; Recombinant Proteins; Treatment Outcome; X-Ray Microtomography | 2014 |
New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Topics: Animals; Beta Particles; Cell Transformation, Neoplastic; Colorectal Neoplasms; Dideoxynucleosides; Female; Heterocyclic Compounds, 1-Ring; HT29 Cells; Humans; Lutetium; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Oligopeptides; Positron-Emission Tomography; Radioisotopes; Receptors, Urokinase Plasminogen Activator; Substrate Specificity | 2012 |